TG Therapeutics CEO Michael S. Weiss to Speak at 8th Annual Evercore Healthcare Conference

TG Therapeutics' CEO will speak at the Evercore Healthcare Conference on December 2, 2025, with a live webcast available.

Quiver AI Summary

TG Therapeutics, Inc. announced that its Chairman and CEO, Michael S. Weiss, will participate in the 8th Annual Evercore Healthcare Conference from December 2 to 4, 2025, with a fireside chat scheduled for December 2 at 12:30 PM ET. The event's live webcast will be accessible on the company's website. TG Therapeutics is focused on developing therapies for B-cell diseases and has FDA approval for its treatment BRIUMVI® (ublituximab-xiiy) for multiple sclerosis. The company has a robust research pipeline and has received additional regulatory approvals for BRIUMVI outside the U.S. Further details can be found on their website and social media platforms.

Potential Positives

Participation of CEO Michael S. Weiss in a prominent healthcare conference, highlighting company leadership and potential investor interest.
Live webcast of the fireside chat provides transparency and accessibility for investors and the public.
FDA approval of BRIUMVI® positions the company as a key player in treating B-cell diseases, enhancing its marketability and reputation.
Global regulatory approvals for BRIUMVI expand the company's reach and potential customer base beyond the U.S.

Potential Negatives

None

FAQ

When will Michael S. Weiss speak at the Evercore Healthcare Conference?

Michael S. Weiss will participate in the conference on December 2, 2025, at 12:30 PM ET.

Where can I watch the fireside chat live?

The fireside chat will be available on the Events page of TG Therapeutics' website.

What is TG Therapeutics focused on?

TG Therapeutics develops and commercializes novel treatments for B-cell diseases.

What is BRIUMVI® used for?

BRIUMVI® is approved for treating adult patients with relapsing forms of multiple sclerosis.

How can I contact investor relations at TG Therapeutics?

You can email investor relations at [email protected] or call 1.877.575.TGTX (8489), Option 4.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$TGTX Insider Trading Activity

$TGTX insiders have traded $TGTX stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $TGTX stock by insiders over the last 6 months:

SAGAR LONIAL sold 20,852 shares for an estimated $672,268
YANN ECHELARD has made 0 purchases and 2 sales selling 15,000 shares for an estimated $532,250.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$TGTX Hedge Fund Activity

We have seen 149 institutional investors add shares of $TGTX stock to their portfolio, and 228 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DEERFIELD MANAGEMENT COMPANY, L.P. removed 2,677,500 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $96,363,225
SOLEUS CAPITAL MANAGEMENT, L.P. added 1,600,796 shares (+71.3%) to their portfolio in Q3 2025, for an estimated $57,828,755
CLEARBRIDGE INVESTMENTS, LLC added 1,591,919 shares (+52.2%) to their portfolio in Q3 2025, for an estimated $57,508,073
WELLINGTON MANAGEMENT GROUP LLP removed 1,168,995 shares (-95.1%) from their portfolio in Q3 2025, for an estimated $42,229,944
MAN GROUP PLC added 868,697 shares (+621.5%) to their portfolio in Q3 2025, for an estimated $31,381,679
FMR LLC removed 840,630 shares (-54.2%) from their portfolio in Q3 2025, for an estimated $30,367,758
DRIEHAUS CAPITAL MANAGEMENT LLC removed 807,833 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $29,182,967

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$TGTX Analyst Ratings

Wall Street analysts have issued reports on $TGTX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 10/06/2025
B. Riley Securities issued a "Buy" rating on 09/17/2025

To track analyst ratings and price targets for $TGTX, check out Quiver Quantitative's $TGTX forecast page.

$TGTX Price Targets

Multiple analysts have issued price targets for $TGTX recently. We have seen 3 analysts offer price targets for $TGTX in the last 6 months, with a median target of $55.0.

Here are some recent targets:

Eric Joseph from JP Morgan set a target price of $49.0 on 11/03/2025
Emily Bodnar from HC Wainwright & Co. set a target price of $60.0 on 10/06/2025
Mayank Mamtani from B. Riley Securities set a target price of $55.0 on 09/17/2025

Full Release

NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 8 ^th Annual Evercore Healthcare Conference, which is taking place from December 2 - 4, 2025. The fireside chat is scheduled to take place on Tuesday, December 2, 2025, at 12:30 PM ET.

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events .

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI ^® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn .

BRIUMVI ^® is a registered trademark of TG Therapeutics, Inc.

CONTACT:
Investor Relations
Email: [email protected]
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations
Email: [email protected]
Telephone: 1.877.575.TGTX (8489), Option 6